Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
Phase 3 N=263 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Cataract Extraction
Primary: Resolution of Post Operative Inflammation — 58.0; 27.3 % of participants with a score of 0
Phase 3 N=248 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Cataract Extraction · Pain · Inflammation
Primary: Resolution of Post Operative Inflammation — 46.3; 25.6 % of participants with a score of 0
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
N/A N=49 Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Pseudophakia · Inflammation
Primary: Investigate Clinical Outcomes for Intraocular Pressure After Treatment With Lotemax (Loteprednol Ophthalmic Solution) 0.5% QID in Subjects Who Have Undergone Cataract…
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
Phase 3 N=378 Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Participants With ACC Count = 0 at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication — 48; 10 Participants — p=<0.001
Phase 2 N=256 Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
Inflammation · Pain · Cataract
Primary: Proportion of Subjects With Clearing of Anterior Inflammation — 18; 18; 13 Participants
Phase 3 N=260 Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
Inflammation and Pain Associated With Cataract Surgery
Primary: Proportion of Participants With Anterior Chamber Cell (ACC) Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT)…
Phase 3 N=406 Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
Inflammation · Pain
Primary: Resolution of Anterior Chamber Cells (ACC). — 62; 33 Eyes — p=<0.001
Phase 4 N=79 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
N/A N=50 Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Cataract · Retinal Edema · Inflammation
Primary: Treatment of Inflammation Associated With Cataract Surgery — 0.01; 0.01 units on a scale
Phase 4 N=64 Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
Cataract
Primary: The Percentage of Patients With a Score of Zero for Anterior Chamber Cells. — 91.7 Percentage of participants
Phase 4 N=50 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)
Post Operative Anterior Chamber Inflammation (Flare)
Primary: Anterior Chamber Inflammation (Flare) — 24.48; 21.93 photon count per msec (pc/ms)
Phase 2 N=132 A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain After Cataract Surgery
Primary: Number of Treatment Emergent Adverse Events — 4; 7; 3; 8 Participants
Phase 3 N=311 Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 32; 12 Participants
Phase 2 N=415 Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
Cataract · Inflammation
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 35; 19; 15; 47 Participants
Phase 3 N=246 2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
Inflammation and Pain Associated With Cataract Surgery
Primary: Number of Participants With Anterior Chamber Cell Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT) Population…
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105
Phase 4 N=126 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Cataracts
Primary: Aqueous PGE2 Inhibition — 288.7; 320.4; 224.8 pg/ml
Phase 3 N=370 Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
Ocular Inflammation and Pain After Cataract Surgery
Primary: Participants With ACC Count = 0 in the Operated Study Eye at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication — 49; 16…
Phase 3 N=380 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
Ocular Infections, Irritations and Inflammations
Primary: Resolution of Anterior Chamber Cells — 48; 39; 19 Participants — p=.0024
Phase 3 N=369 Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Cataract · Inflammation · Surgery
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 49; 15 Participants